Hemostemix Inc. (CVE:HEM – Get Free Report)’s share price hit a new 52-week low during trading on Thursday . The stock traded as low as C$0.04 and last traded at C$0.05, with a volume of 45000 shares traded. The stock had previously closed at C$0.04.
Hemostemix Price Performance
The firm has a market cap of C$6.10 million, a PE ratio of -2.33 and a beta of 0.62. The business has a fifty day moving average price of C$0.05 and a two-hundred day moving average price of C$0.06.
Hemostemix Company Profile
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions. The company develops cell therapy products from the patient's own blood, which is a non-invasive source of therapeutic cells. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia in Canada and the United States.
Featured Articles
- Five stocks we like better than Hemostemix
- 5 discounted opportunities for dividend growth investors
- What’s Behind Walgreens Stock Plunge: What Investors Can Do Next
- What Does a Stock Split Mean?
- MarketBeat Week in Review – 6/24 – 6/28
- 3 Best Fintech Stocks for a Portfolio Boost
- General Mills Stock Drops After Revenue Miss in Fiscal Q4 2024
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.